Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 6.31
- Piotroski Score 3.00
- Grade Neutral
- Symbol (CERE)
- Company Cerevel Therapeutics Holdings, Inc.
- Price $44.96
- Changes Percentage (0.74%)
- Change $0.33
- Day Low $44.96
- Day High $44.99
- Year High $44.99
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I clinical trial for the treatment of substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder; and CVL-047, selective PDE4 inhibitor for the treatment of major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and an LRRK2 inhibitor program to address disease progression in Parkinson's. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 08/07/2024
- Fiscal Year End N/A
- Average Stock Price Target $33.50
- High Stock Price Target $40.00
- Low Stock Price Target $27.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.73
- Trailing P/E Ratio -14.66
- Forward P/E Ratio -14.66
- P/E Growth -14.66
- Net Income $-432,842,000
Income Statement
Quarterly
Annual
Latest News of CERE
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Ceres Power Holdings First Half 2024 Earnings: UK£0.065 loss per share (vs UK£0.14 loss in 1H 2023)
Ceres Power Holdings reported a revenue of UK£28.5m (up 144%) and a net loss of UK£12.6m (52% improvement) in the trailing 12 months. Future revenue is expected to grow 22% annually....
By Yahoo! Finance | 1 day ago -
Chad Mascoe Jr. and Sincere Brown connect for 3 TDs, Campbell gains wild 44-41 win over Delaware St.
Campbell secured a thrilling 44-41 win against Delaware State with a late touchdown pass from Chad Mascoe Jr. to Sincere Brown. The game featured multiple lead changes and a dramatic fourth quarter....
By AP NEWS | 2 days ago -
Memorials, ceremonies and activities planned across Manitoba to mark Orange Shirt Day - Winnipeg | Globalnews.ca
National Day for Truth and Reconciliation, or Orange Shirt Day, on Sept. 30 in Manitoba recognizes the impact of Canada's residential schools, honoring survivors and those who did not return home. Var...
By Global News | 3 days ago
